AbbVie

Biotechnology
ABBV
$ 143 (1.3)%
Share price
$ 252 bn
Market Cap
$ 316 bn
Enterprise Value

Carbon footprint

2 Ton
GHG emissions per $ 1 mln investment
0.05x the weighted average for S&P 500
FY2021
How is this calculated?
+22%
YOY change in GHG emissions
Stronger than the +4.9% weighted average for S&P 500
FY2021 vs. previous year

Primary Climate Goal

-5.4%
Proj. YOY change in GHG emissions (Scope 1 + 2)
Weaker than the -6.6% weighted average for S&P 500
FY2022
How is this calculated?

AbbVie aims to reduce Scope 1 + 2 by 25% by 2025 from a base year 2015


This target has not been verified as science based according to SBTi
AbbVie's actual and proj. GHG emissions (Scope 1 + 2) (Kt of CO2e)

GHG emissions and Carbon intensity

AbbVie's GHG emissions (market-based) (Kt of CO2e)
AbbVie's Carbon intensity (Tons per 1 USDm)

AbbVie's carbon footprint

AbbVie reported Total CO2e Emissions - Market-Based Scope 1 + Scope 2 for the twelve months ending 31 December 2021 at 625 Kt (+112/+22% y-o-y). At the sime time, carbon intensity declined marginally to 11 t (-0.1 /-0.9% y-o-y).

No public disclosure of Scope 3 emissions has been found for AbbVie at the moment.

The company is committed to reducing Scope 1 + 2 by 25% by 2025 from a base year 2015, which translates into the estimated reduction of -34 Kt per annum over the period of FY2022 - FY2025. This target, however, has not been recognised as science-based (and as aligned with Paris Agreement) by the SBTi.

Company environmental metrics

Show more...